WARSAW, Ind., Aug. 6 /PRNewswire-FirstCall/ -- Symmetry Medical Inc. , a leading independent provider of products to the global orthopaedic device industry and other medical markets, announced second quarter 2009 financial results for the period ended July 4, 2009.
Revenue for the second quarter 2009 was $101.0 million, compared to $109.8 million reported in the second quarter 2008. Revenues during the quarter were unfavorably impacted by a foreign currency translation effect of $5.9 million.
Selling, general and administrative expenses were $13.2 million for the second quarter 2009, down 11.4% from $14.9 million for the second quarter 2008. The year-over-year decrease reflected the elimination of professional fees related to the Sheffield, UK investigation, cost savings and improved operating efficiencies during the second quarter 2009. These savings were partially offset by a $0.5 million increase in non-cash compensation expense. Second quarter 2008 included investigation costs of approximately $1.4 million.
The second quarter 2009 included a non-cash gain of $0.2 million in the mark to market of the Company's interest rate derivative, compared to a non-cash gain of $1.4 million in the second quarter 2008. This $1.2 million unfavorable year-over-year comparison was partially offset by favorable taxes in the second quarter of 2009.
Net income for the second quarter 2009 was $9.0 million, or $0.25 per diluted share, up from net income of $6.2 million, or $0.17 per diluted share, for the second
quarter of 2008.
Brian Moore, President and Chief Executive Officer of Symmetry Medical, stated, "We are pleased with our strong second quarter 2009 bottom line performance. It reflects initiatives we undertook in anticipation of a continuing slowdown in the economy and challenging conditions certain sectors of our business. These early initiatives reduced our SG&A costs and resulted in operational efficiencies that improved our gross profit. We are particularly encouraged that Sheffield has reached operating profitability. We expect further improvement at that facility as it benefits from solid pricing and material cost savings."
Financial Guidance
For the full year 2009, Symmetry is adjusting its previously stated annual revenue guidance to a range of $385 million to $405 million, from $405 million to $420 million. This adjustment reflects second quarter 2009 results, current order flow and anticipated customer demand for the remainder of the year. Notwithstanding these challenges, the Company is reaffirming full year 2009 earnings guidance within the range of $0.77 to $0.85 per diluted share, as a result of strong second quarter 2009 performance, improved performance at Sheffield, additional efficiencies and cost controls across the business.
Symmetry Medical will host a conference call to discuss the second quarter 2009 earnings at 8:00 a.m. ET on August 6, 2009. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate web site at www.symmetrymedical.com. The dial-in numbers are (800) 561-2693 for domestic callers and (617) 614-3523 for international. The reservation number for both is 75125435. After the live webcast, the call will remain available on Symmetry Medical's web site through October 6, 2009. In addition, a telephonic replay of the call will be available until August 13, 2009. The replay numbers are (888) 286-8010 for domestic callers and (617) 801-6888 for international callers. Please use reservation code 44821864 to access the call.
Symmetry Medical Inc. is a leading independent provider of implants and related instruments and cases to the orthopaedic device industry. The Company also designs, develops and produces these products for companies in other segments of the medical device market, including arthroscopy, dental, laparoscopy, osteobiologic and endoscopy sectors and provides limited specialized products and services to non-healthcare markets, such as the aerospace market.
Statements in the press release regarding Symmetry Medical Inc.'s business which are not historical facts may be "forward-looking statements" that involve risks and uncertainties, within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are predictive in nature and are frequently identified by the use of terms such as "may," "might," "will," "should," "expect," "believe," "anticipate," "plan," "estimate," "intend," and similar words indicating possible future expectations, events or actions. Such predictive statements are not guarantees of future performance, and actual outcomes and results could differ materially from our current expectations. We refer you to the "Risk Factors" and "Forward Looking-Statements" sections in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission as well as the Company's other filings with the SEC, which are available on the SEC's Web site at www.sec.gov.
SOURCE Symmetry Medical Inc.
CONTACT: Investors-Media: Nick Laudico, +1-646-536-7030,
nlaudico@theruthgroup.com, Jason Rando, +1-646-536-7025,
jrando@theruthgroup.com, both of The Ruth Group; or Fred Hite, Symmetry
Medical Inc., Senior Vice President, Chief Financial Officer,
+1-574-371-2218
Web site: http://www.symmetrymedical.com/
